Skip Navigation


Annals of Oncology Advance Access originally published online on February 21, 2008
Annals of Oncology 2008 19(5):829-830; doi:10.1093/annonc/mdn016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/5/829    most recent
mdn016v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Labianca, R.
Right arrow Articles by Torri, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labianca, R.
Right arrow Articles by Torri, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorials

Predicting response of molecular targeted therapies: a still possible challenge?

R. Labianca1,*, M. Garassino2 and V. Torri3

1 Divisione di Oncologia Medica, Ospedali Riuniti, Bergamo
2 Divisione di Oncologia Medica, Ospedale Fatebenefratelli, Milano
3 Dipartimento di Oncologia, Istituto ‘Mario Negri’, Milano, Italy

* E-mail: rlabian@tin.it

The first 10% of the full text of this article appears below.

Over the past few years, the development of antitumoral molecular targeted strategies has been replacing the more empiric screening way of research for new cytotoxic drugs. The understanding of the molecular mechanisms which underline carcinogenesis has improved and favored the development of a pattern of targeted drugs that can specifically inhibit cancer pathways and key molecules implicated in different phases of tumor growth and metastases. Despite these efforts, even though some of these new compounds have shown progress, failure rates are still common and impact on survival is modest.

Epidermal growth factor receptor (EGFR) represents an interesting example of a genetically validated target which has partially failed to demonstrate . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?